Effect of the receptor activator of nuclear factor [ka]B and rank ligand on in vitro differentiation of cord blood CD133[+] hematopoietic stem cells to osteoclasts
Cell Journal [Yakhteh]. 2016; 18 (3): 322-331
en Inglés
| IMEMR
| ID: emr-183766
ABSTRACT
Objective:
receptor activator of nuclear factor-kappa B ligand [RANKL] appears to be an osteoclast-activating factor, bearing an important role in the pathogenesis of multiple myeloma. Some studies demonstrated that U-266 myeloma cell line and primary myeloma cells expressed RANK and RANKL. It had been reported that the expression of myeloid and monocytoid markers was increased by co-culturing myeloma cells with hematopoietic stem cells [HSCs]. This study also attempted to show the molecular mechanism of RANK and RANKL on differentiation capability of human cord blood HSC to osteoclast, as well as expression of calcitonin receptor [CTR] on cord blood HSC surface
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Idioma:
Inglés
Revista:
Cell J. [Yakhteh]
Año:
2016
Similares
MEDLINE
...
LILACS
LIS